| Autor: |
Ronald F van Vollenhoven, Merete Lund Hetland, Till Uhlig, Espen A Haavardsholm, Dan Nordström, Mikkel Østergaard, Michael T Nurmohamed, Sizheng Steven Zhao, Alf Kastbom, Bjorn Gudbjornsson, Meliha Crnkic Kapetanovic, Gerður Gröndal, Yuan Zhang, Kim Hørslev-Petersen, Anna Rudin, Jon Lampa, Kristina Lend, Tuulikki Sokka-Isler, Annika Söderbergh, Milad Rizk, Cristina Maglio, Marte Schrumpf Heiberg, Violetta Dubovyk, Georgios K Vasileiadis, Tahzeeb Fatima |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
RMD Open, Vol 10, Iss 2 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2056-5933 |
| DOI: |
10.1136/rmdopen-2024-004227 |
| Popis: |
Objective This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological antirheumatic treatment in early rheumatoid arthritis (RA).Methods This report included 793 participants with untreated early RA from the randomised, longitudinal NORD-STAR trial, all of whom had their body mass index (BMI) assessed at baseline. Obesity was defined as BMI ≥30 kg/m2. All participants were randomised 1:1:1:1 to one of four treatment arms: active conventional treatment, certolizumab-pegol, abatacept and tocilizumab. Clinical and laboratory measurements were performed at baseline and at 8, 12, 24 and 48-week follow-up. The primary endpoint for this report was response to treatment based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI) remission and Disease Activity Score with 28 joints using C-reactive protein (DAS28-CRP) |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
